Sanofi (NASDAQ:SNY) Shares Sold by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC decreased its position in shares of Sanofi (NASDAQ:SNYFree Report) by 6.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,526 shares of the company’s stock after selling 1,113 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Sanofi were worth $822,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in SNY. Rise Advisors LLC grew its stake in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC grew its stake in shares of Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares during the period. Frazier Financial Advisors LLC acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $28,000. Finally, McIlrath & Eck LLC grew its stake in shares of Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock worth $30,000 after purchasing an additional 361 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Trading Down 0.1 %

Shares of SNY stock opened at $49.21 on Wednesday. The stock’s fifty day moving average is $48.29 and its two-hundred day moving average is $48.39. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The firm has a market capitalization of $124.49 billion, a P/E ratio of 24.73, a PEG ratio of 1.54 and a beta of 0.60. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $55.72.

Sanofi (NASDAQ:SNYGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.96. The company had revenue of $11.36 billion for the quarter, compared to analyst estimates of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. Research analysts expect that Sanofi will post 4.11 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is presently 74.37%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on SNY shares. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $55.00.

View Our Latest Stock Report on Sanofi

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Articles

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.